Full TitleA Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma
Radiation therapy and bevacizumab are both treatments for malignant gliomas. However, giving radiation therapy after an initial course of treatment has been completed can cause scar tissue and neurologic symptoms. Preliminary evidence indicates that giving radiation with bevacizumab may be more effective than giving either treatment alone.
In this study, researchers want to find the highest dose of radiation therapy that can be given with bevacizumab in patients with glioma that has stopped responding to prior radiation therapy and/or chemotherapy. The radiation will be delivered through a targeted approach called stereotactic radiosurgery.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of glioma that has stopped responding to prior radiation therapy and/or chemotherapy.
- At least 3 months must have passed since prior radiation therapy and 4 weeks since any prior chemotherapy and entry into the study.
- Patients may not have received prior radiosurgery or bevacizumab.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact the Brain Tumor Hotline at 212-639-6767.